Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome (ANDAMAN)

  • STATUS
    Recruiting
  • End date
    Dec 19, 2023
  • participants needed
    2574
  • sponsor
    Assistance Publique - Hôpitaux de Paris
Updated on 25 January 2022
diabetes
angiography
stenosis
aspirin
clot
electrocardiogram
chest pain
diabetes mellitus
obesity
fasting
hba1c
stemi
troponin
ischemia
cardiac troponin
q waves
acute coronary syndrome
hemoglobin a1c
glycosylated hemoglobin

Summary

To compare treatment with Aspirin Protect twice a day (100 mg in the morning and 100 mg in the evening) versus Aspirin Protect 100 mg once per day on a composite end-point of ischemic events in diabetic patients, or in patients with a known risk factor for non-optimal aspirin response (obesity, abdominal obesity or coronary event occurring with long-term aspirin),with acute coronary syndrome. It is expected that aspirin taken twice a day will reduce the occurrence of new ischemic event after acute coronary syndrome in diabetic patients or in patients with a known risk factor.

Description

Patients who show high persistent platelet reactivity under aspirin are increasingly becoming an issue of clinical concern. Several studies have suggested that giving aspirin more frequently is very effective for reducing aspirin high persistent platelet reactivity, especially in diabetic patientsor in patients with a known risk factor. The aim of the study is to evaluate low dose of aspirin twice a day (compared to once a day) for the reduction of ischemic events in diabetic patients or in patients with a known risk factor, with acute coronary syndrome.

Experimental Design:

A multicenter, randomised, parallel group comparing aspirin given twice a day compared to once per day in diabetic patients, or in patients with a known risk factor for non-optimal aspirin response (obesity, abdominal obesity or coronary event occurring with long-term aspirin),with acute coronary syndrome.

Primary objective:

To compare treatment with Aspirin Protect twice a day (100 mg in the morning and 100 mg in the evening) versus Aspirin Protect 100 mg once per day on a composite end-point of ischemic events in diabetic patients, or in patients with a known risk factor for non-optimal aspirin response (obesity, abdominal obesity or coronary event occurring with long-term aspirin),with acute coronary syndrome.

Secondary objectives:

  • To compare treatment with Aspirin Protect twice a day (100 mg in the morning and 100 mg in the evening) versus Aspirin Protect 100 mg once per day on net clinical benefit combining the ischemic and bleeding events in diabetic patients, or in patients with a known risk factor for non-optimal aspirin response (obesity, abdominal obesity or coronary event occurring with long-term aspirin),with acute coronary syndrome.
  • To compare treatment with Aspirin Protect twice a day (100 mg in the morning and 100 mg in the evening) versus Aspirin Protect 100 mg once per day on cardiac events in diabetic patients, or in patients with a known risk factor for non-optimal aspirin response (obesity, abdominal obesity or coronary event occurring with long-term aspirin),with acute coronary syndrome.
  • To compare treatment with Aspirin Protect twice a day (100 mg in the morning and 100 mg in the evening) versus Aspirin Protect 100 mg once per day in each of individual component of the main criterion.
  • To confirm the safety of the innovative strategy (aspirin twice a day) concerning major bleeding events.

Study enrollment:

Multicentric national study involving 42 centers in France The duration is expected to be 24 months of recruitment. Patients will be randomized during the index hospitalization for acute coronary syndrome and before discharge between a conventional strategy of enteric coated aspirin 100mg per day with the standard of care or a innovative strategy of enteric coated aspirin 100mg morning and evening. Patients will be followed at one month, six months, one year and 18 months

Statistical analysis:

The study will include 2574 patients. We hypothesized that at 18 months, there will be an event rate of 22% for "death, MI, stroke, urgent revascularization, or acute arterial thrombotic event in the group treated with aspirin and we expect a decrease of the primary event of 20% (relative variation) using aspirin twice a day corresponding to an event rate of 17.6%.

A sample size of 1287 patients /group will allow an 80% power to detect this difference using a log-rank test at a two-sided 5% significance level. The study will include 2574 diabetic patients, or patients with a known risk factor for non-optimal aspirin response.

The primary analysis is based on the Intention To Treat population and the primary endpoint. The primary analysis on the primary endpoint will be carried out using a log-rank test for survival analysis. The 95% confidence interval of the hazard ratio will be presented. In addition the survival status during 18 months follow-up will be described by showing Kaplan-Meier curves.

Primary outcome according to pre-specified subgroups:

  • Age: patients < 75 years or patient 75 years
  • Gender: male or female
  • Insulin vs no insulin treatment
  • Type of acute coronary syndrome : STEMI vs NSTEMI
  • Type of ADP inhibitor cotreatment
  • Treatment strategy medical vs invasive (angioplasty or CABG surgery)
  • Peripheral artery disease Yes/No
  • GRACE score > or 140
  • Left ventricular ejection fraction > or 40%
  • Prior stroke Yes/No
  • previous treatment with aspirin Yes/No
  • initial HbA1C level > or 8%
  • duration of diabetes > or 10 years
  • Weight <60; 60-90; >90kg
  • PPI use Yes/No

Details
Condition Diabetes Mellitus, Acute Coronary Syndrome, Coronary Artery Disease, Obesity
Treatment Novel strategy Aspirin, Conventional strategy Aspirin
Clinical Study IdentifierNCT02520921
SponsorAssistance Publique - Hôpitaux de Paris
Last Modified on25 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

_ Diabetes mellitus defined as ( 1 item)
Treated diabetes mellitus
fasting glucose levels 7 mmol/l after admission
glucose level 11 mmol/l after admission (any moment)
HbA1C 6.5%
OR
Factor of aspirin lack of efficacy defined as ( 1 item)
Obesity defined as BMI27kg/m2
Waist circumference 88cm for women or 102cm for men
Index event occurring under chronic low dose of aspirin (<300mg)
Acute coronary syndrome defined as
Acute coronary syndrome with ST-segment elevation (STEMI) is defined as chest pain ( 30min) with persistent ST-segment elevation in at least two contiguous leads (1mm) or a new left bundle-branch block and the intention to perform primary PCI or thrombolysis
Acute coronary syndrome without ST-segment elevation (NSTEMI) is defined as universal myocardial definition: Detection of cardiac biomarker values elevation [preferably cardiac troponin (cTn)] with at least one value above the 99th percentile upper reference limit (URL) and with at least one of the following
Symptoms of ischemia
New or presumed new significant ST-segment-T wave (ST-T) changes except ST elevation
Development of pathological Q waves in the ECG
Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
Identification of an intracoronary thrombus by angiography
included after the angiography showing stenosis 50% and before discharge
signed informed consent and 18 years old

Exclusion Criteria

Allergy or contraindication to aspirin (Hypersensitivity to aspirin or any of the excipients, history of asthma induced by the administration of salicylates, ongoing peptic ulcer, constitutional or acquired haemorrhagic disease including gastrointestinal bleeding, history of hemorrhagic stroke and thrombocytopenia, pregnancy after 24 weeks of gestation, risk of bleeding, severe renal failure, severe hepatic impairment, uncontrolled severe heart failure
Concomitant anticoagulation therapy that cannot be stopped
Fibrinolytic therapy less than 24 hours
Unstable patients according to investigator: use of amine or mechanical device (IABP, ECMO or similar) or mechanical ventilation during index hospitalization
Index event is an acute complication of coronary revascularization (PCI or CABG)
Known serious hematological disorder
Proven gastric or duodenal ulcer in the past 3 months
Previous hemorrhagic stroke, previous cranial bleeding, intracranial neoplasia, arterio-venous malformation
Any condition that may put the patient at risk or influence study result in the investigators' opinion (active cancer .) or that increase the risk for non-compliance or being lost to follow-up
Concomitant treatment with methotrexate or with chronic non-steroidal anti-inflammatory drug
Pregnancy or lactation or woman of childbearing age without contraception
Participant in an another investigational drug study within 30 days
Patients under curatorship
No social security
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note